

ABOUT THE CONFERENCE

India is fast becoming a global hub for advanced biologics and precision therapeutics with peptide therapy at the heart of this transformation. The Peptide Therapeutics Summit 2025 is a focused, one-day strategic forum bringing together leading scientists, regulatory authorities, manufacturers, and industry innovators to explore the latest breakthroughs and pressing challenges in peptide-based drug development.

Designed to ignite meaningful dialogue and drive actionable insights, this summit will cover the entire peptide therapeutics value chain—from early-stage research to large-scale commercialization. Key discussions will dive into critical areas such as regulatory navigation, formulation development, and the transition from gram-scale to kilogram-scale production.

With sessions led by domain experts, the conference will address: The challenges of bringing novel therapeutic modalities to market, Choosing the optimal path for scalable, cost-effective manufacturing, Overcoming formulation development hurdles and Strategies for successful scale-up and regulatory approval.

Tailored for professionals working across the peptide therapeutics ecosystem, this event offers fresh regulatory intelligence, practical tools for compliance, and forward-thinking strategies to accelerate innovation while ensuring patient safety.

INDUSTRY OVERVIEW

The peptide therapeutics market in India is expected to reach a projected revenue of US\$ 2,265.8 million by 2030. A compound annual growth rate of 13.8% is expected of India peptide therapeutics market from 2024 to 2030.

The India peptide therapeutics market generated a revenue of USD 984.7 million in 2023 and is expected to reach USD 2,265.8 million by 2030. The India market is expected to grow at a CAGR of 12.6% from 2024 to 2030. In terms of segment, metabolic disorders was the largest revenue generating application in 2023. Metabolic disorders is the most lucrative application segment registering the fastest growth during the forecast period followed by oncology, cardiovascular diseases, infectious diseases, pain management and more.





WHY ATTEND

20+ Expert Speakers

Networking opportunity with 50+ people from the peptides industry Expert opinion from the best of the industry on the prospects and the Latest Developments in the industry will be discussed

Exhibitors providing Innovative Solutions for the industry



WHO SHOULD ATTEND

DEPARTMENT

Research and Development (R&D)

Drug Discovery and Development

Manufacturing &
Process Development

Quality Assurance & Quality Control

Researchers and Scientists

Analytical Development

Pharmaceutical and Biotech Industry Professionals

Regulatory and Compliance Experts



WHY PARTNER

One of its kind of platforms with key focus on from a 360-degree approach.

An opportunity to connect with more than 50+ peptides industry professionals.

Top speakers from the industry majorly the Directors, Presidents, VPs of top peptides companies, regulatory authorities and government bodies.

Visibility of vendor's product with primary industry decision-makers.

Increased brand awareness and visibility.

WHO SHOULD PARTNER

Reagents, coupling agents and raw materials

Lab equipment's

Flow reactors and other equipment's

Peptides for research, clinical trials, therapeutic manufacturing

Injectable supplies

CMO/CDMO

Peptide synthesis

CRO

Purification



KEY HIGHLIGHTS



9 hours of engaging content across 1 day



20+ Speakers



Panel discussions, Roundtables and fire side chats



50+ Professionals under one roof



Networking session

KEY TOPICS

Navigating the
Challenges of
Bringing New
Therapeutic
Modalities to
Market: A Deep
Dive into Technical
and Regulatory
Considerations

The Manufacturing
Dilemma: Synthetic
or Recombinant –
Choosing the Right
Path for Scalable
and Cost-Effective
Production

From Bench to Approvals: Regulatory Complexities Peptides & Oligonucleotide Approvals Scaling Peptide
Production:
Overcoming
Challenges from
Grams to
Kilograms

Greener Peptide Manufacturing: Reducing Solvent Use and Managing Waste



SPEAKERS 2025



Satyajit Tillu Technical Services Head-Peptides **Piramal Pharma**



Nilesh Patil

Dy. General manager - Peptide Dept

Shilpa Pharma Lifesciences Limited



Manoj Kumar Pananchukunnath Chief Scientific Officer ELT Member Biocon



Dipak Kalita
Senior Vice President - R&D
Shilpa Pharma Lifesciences Limited



Dr. Ashutosh KumarProfessor - Department of Biosciences and Bioengineering **IIT Bombay**



Shubhadeep Sinha
Senior Vice President,
Head - Clinical Development &
Medical Affairs (CD&MA)
Hetero



Shailendra Gaur Director – Process Development Aspergen Inc



Dr. Tathagata DuttaPresident **Jodas Expoim**



Darshan Aigal
Head Regulatory Affairs Complex Generics
and Biologics
Cipla Ltd.



Ranjan Chakrabarti Biopharma Professional



Amol Sonawane
Associate Director - Bio-Clinical Studies
Ferring Pharmaceuticals



Dr. Akhil Kumar Chief Medical Officer Aurigene Oncology



Ashish Dwivedi
Principal Scientist & Lead- Peptides &
Complex Injectables
Alembic Pharmaceuticals Limited



Hosahudya N Gopi Professor - Chemistry IISER Pune

Peptides Therapeutics Summit

11th November 2025 Hyderabad

Advancing Therapeutics Through Peptide Innovation - Transforming Medicine Molecule by Molecule

Tuesday, 11th November 2025

	08:00 - 09:45	Registration & Networking	
	09:45 – 10:00	Opening Remarks from Informa Markets in India	
	10:00 – 10:15	Keynote Session: Peptide Therapy on the Rise: Advancing Therapeutics in India Manoj Kumar Pananchukunnath, Chief Scientific Officer ELT Member, Biocon	
	10:15 – 11:00	 Leadership Panel Discussion: Navigating the Challenges of Bringing New Therapeutic Modalities to Market: A Deep Dive into Technical and Regulatory Considerations Addressing issues like degradation, short half-life, and delivery route limitations Regulatory landscape for current global guidelines, approvals, and data requirements Ensuring consistency, purity, and cost-effectiveness in large-scale peptide synthesis and formulation Accelerate clinical translation of novel peptide therapies maintaining compliance and qualit Panellist: Manoj Kumar Pananchukunnath, Chief Scientific Officer ELT Member, Biocon Dr Shubhadeep Sinha, Senior VP, Head - Clinical Development & Medical Affairs (CD&MA), Heter Dr.Akhil Kumar, Chief Medical Officer, Aurigene Oncology Dr.Tathagata Dutta, President, Jodas Expoim Ashish Dwivedi, Principal Scientist & Lead- Peptides & Complex Injectables, Alembic 	
	11:00 – 11:30	Addressing Formulation Development Challenges for Peptide Managing degradation	
		Managing degradation	

Reserved for Sponsor

11:30 – 12:00 Networking Coffee Break 12:00 – 12:45 Panel Discussion: The Manufacturing Dilemma: Synthetic or Recombinant – Choosing the Right Path for Scalable and Cost-Effective Production • Evaluating cost, purity, yield, and complexity between synthetic and recombinant approaches • Assessing which method better supports gram-to-kilogram scale-up • Quality & Regulatory Impact: Understanding how each route aligns with GMP and regulatory expectations Moderated By: Dr. Ranjan Chakrabarti, Biopharma Professional

Ensuring consistent quality in large-scale production Navigating evolving guidelines for peptide formulations

Overcoming poor oral bioavailability and degradation through innovative delivery systems

Peptides Therapeutics Summit

11th November 2025 Hyderabad

	Panellist: Nilesh Patil, Dy. General manager - Peptide Dept, Shilpa Pharma Lifesciences Ltd. Shailendra Gaur, Director- Process Development, Aspergen Inc
12:45 – 13:05	Peptide Therapy: Beyond Optimization – Treating Serious Health Conditions
	 Exploring peptides in treating cancer, metabolic disorders, infectious diseases, and rare genetic conditions Case studies and late-stage clinical trials of peptide-based drugs Future Outlook: Opportunities for personalized peptide therapies and their integration with
	platforms like mRNA and CRISPR
	Reserved for Sponsor
13:05 – 13:35	NMR Spectroscopy, Spectral Signatures, Pattern Recognition for HOS based Biologics
	 Exposition of high-resolution NMR techniques and other orthogonal biophysical techniques to understand the HOS of Biopharmaceuticals in their formulated states Establishing the HOS of Biologics drugs and their quality assurance or control
	Dr. Ashutosh Kumar, Professor - Department of Biosciences and Bioengineering , IIT Bombay
13:35 – 14:30	Networking Lunch Break
14:30 – 15:00	Advances in Peptide Impurity Profiling
	Prof. Hosahudya N Gopi, Professor- Chemistry, IISER, Pune
15:00 – 15:30	Greener Peptide Manufacturing: Reducing Solvent Use and Managing Waste
	Environmental concerns in peptide production
	 Sustainable waste management practices in peptide manufacturing Exploring eco-friendly alternatives to traditional peptide production methods
	Satyajit Tillu, Technical Services Head-Peptides, Piramal Pharma
15:30 – 16:00	Un-Natural Amino Acids in Peptide Drugs: Benefits and Challenges
	 Improves resistance to enzymatic degradation, extending circulation half-life Creates novel conformations for increased receptor specificity and potency Presents challenges in synthesis scale-up, quality control, and regulatory approval
	Dipak Kalita, Senior Vice President - R&D, Shilpa Pharma Lifesciences Limited
16:00 – 16:15	Networking Coffee Break
16:15 – 16:45	Evolving Regulatory Expectations: From Small Molecules to Peptides to Biologics
	Darshan Aigal, Head Regulatory Affairs Complex Generics & Biologics , Cipla Ltd

Peptides Therapeutics Summit

11th November 2025 Hyderabad

16:45 – 17:15 The Future of Targeted Therapy in India: Integrating CRISPR and Peptide Platforms

- Explore how combining CRISPR with peptide-based delivery systems enhances therapeutic
- Discuss the potential for CRISPR-peptide integration to enable treatment for complex diseases like cancer, rare genetic disorders, and infectious diseases
- Examine the evolving regulatory frameworks and the need for R\&D infrastructure

Dr.Akhil Kumar, Chief Medical Officer, Aurigene Oncology

End of the Conference

EVENT PARTNERS

Exhibit Partners





TICKET PRICING

Category

Fee (INR per person)

Standard

₹15,000

*Note: (Mandatory 18% GST will be applicable on all bookings.)

CONTACT US:

For Speaking Opportunities

+91 93431 97703 | archana.shantharam@informa.com

For Delegate Registrations

Saleem Pasha

+91 99867 68672 | saleem.pasha@informa.com

Mili Shah

+91 99308 97361 | mili.shah@informa.com

For Sponsorship, Speaking and Exhibit opportunities

Prathamesh Kesarkar

+91 74992 52173 | prathmesh.kesarkar@informa.com

For Marketing Alliances

Shrushti Kamath

+91 91672 26207 | shrushti.kamath.IN@informa.com



Informa Markets India Private Limited, 1st Floor B wing, Unit No 3 and 4, Solitaire XIV, Guru Hargovindji Marg, Chakala, Andheri East, Mumbai Suburban, Maharashtra, 400093